Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
about
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contraEvidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancerProstate cancer is not breast cancerTaxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough StrategyAddition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerAndrogen deprivation therapy as backbone therapy in the management of prostate cancerAndrogen receptor axis-targeted agentsRole of systemic chemotherapy in metastatic hormone-sensitive prostate cancerChemotherapy options in castration-resistant prostate cancerWhat's new in prostate cancer research?Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-AnalysisChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerUsing routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme.[Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilityThe Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.Severe Cushing's syndrome due to small cell prostate carcinoma: a case and review of literature.Metastatic castration-resistant prostate cancer: critical review of enzalutamide.Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trialManagement of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.First Brazilian Consensus of Advanced Prostate Cancer: Recommendations for Clinical Practice.Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysisAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.The role of chemotherapy and new targeted agents in the management of primary prostate cancer.Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.Emerging drugs for prostate cancer.Evolution of androgen receptor targeted therapy for advanced prostate cancer.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.Management of metastatic hormone-sensitive prostate cancer.Corticosteroids in the management of prostate cancer: a critical review.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
P2860
Q24289204-CFFD4A5C-9021-41FD-AB9A-5BC5184EEE5EQ26739738-6BDA140A-0909-40A0-8B87-0E7F01F2D1D1Q26751354-6B1F3282-00DC-41B7-842C-39CD21F3910BQ26770247-3ECBF970-C3E6-44EE-AC1A-F0B7D01FC049Q26771537-B633482F-7933-4264-BDE8-7564F882733CQ26773634-E814C060-04E7-47A3-A087-9C3BF7F18266Q26796568-BAFA787D-9FFF-4E3E-9CA5-AFD94F9A1FADQ27024775-D3974617-5486-478E-BDEA-0F4A36435BA0Q28071795-AD5BD9B9-1D5B-4D89-BF85-F372285DB223Q28074481-51C9A0E0-88D9-4EB1-BD04-51542546F3BBQ28076110-DDAB428C-7E02-4511-8E5A-6008AE436C75Q28078477-4BBA29B8-D3E2-4A5A-A6F0-1F437F24B383Q28078502-C1FEFF08-24FB-47B2-9381-E67997497301Q28550301-388DA282-ADA9-433A-8FDF-B62B8037825EQ30278902-1D4EF1A2-C3F2-4853-8016-B41DBC3C088CQ30912685-D6F4510C-19AC-49FA-95B3-E1779487EA16Q31114538-43D55309-AB01-4EF2-8061-EEFC2F167660Q33656791-4DE8B2B5-CDD5-403F-95EA-5FD19D15806DQ33656820-F53BC259-261E-4353-B3DA-CBEEF0869AA7Q33702987-429726FB-F408-4AC6-A336-F3DBB4051C65Q33904201-CEE98DCF-EBBD-43C2-93EE-018FCF8C6853Q34381852-141B94B0-B622-4C26-AC92-75AEEFE5D9AAQ34993890-BF6E3F61-66C7-421E-9E25-FF473E711585Q35829785-E9892BE9-F71C-4383-B44E-A8B6E5CBACF7Q35879087-601CF7FE-6298-4CAF-A177-C6EAB95B85C7Q35881896-D8DCF363-F5B3-48B2-BF72-A2E68549C1F2Q36152474-FB0AAD76-C4E1-4BA2-9C54-441B59F0B55BQ36280995-E9F5B0CF-E29E-4081-B6C8-E4613017EE59Q36530173-16F18485-7BB5-48B6-961A-99C1C0BB3D3BQ36707077-5BDFF518-A6EA-40B8-9FBF-EEF30CEB08E3Q37496652-4029D8EC-4591-42AC-91F9-E54119FF8E24Q37708171-C4C9FA98-0BE8-4880-9C83-F760F3ED71BDQ38130174-DC81DB3E-572A-45CB-A6A6-CAB7A70933EAQ38166018-C5B48639-EBA0-46ED-9487-71463B7C44DCQ38212716-86EBCBF4-BFA8-4E58-8F9B-767D719B43B9Q38232184-C4DE4D30-AF9A-418E-8C39-2E81F04F1DBEQ38353828-B410917C-1F3A-4DBE-A9A4-CC87CE74A37BQ38353835-CC73B85C-BF98-49CA-9034-747291DE86B1Q38374403-04AB0307-B8A7-4A47-B4F0-37383F23D83AQ38374417-C4727458-6AAF-4DC4-A897-85E38CD9E864
P2860
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Androgen-deprivation therapy a ...... ed, open-label, phase 3 trial.
@en
Androgen-deprivation therapy a ...... ed, open-label, phase 3 trial.
@nl
type
label
Androgen-deprivation therapy a ...... ed, open-label, phase 3 trial.
@en
Androgen-deprivation therapy a ...... ed, open-label, phase 3 trial.
@nl
prefLabel
Androgen-deprivation therapy a ...... ed, open-label, phase 3 trial.
@en
Androgen-deprivation therapy a ...... ed, open-label, phase 3 trial.
@nl
P2093
P50
P1433
P1476
Androgen-deprivation therapy a ...... sed, open-label, phase 3 trial
@en
P2093
Ali Hasbini
Benjamin Esterni
Brigitte Laguerre
Christian Platini
Christine Théodore
Claude El Kouri
Claude Linassier
Damien Pouessel
Etienne Suc
Franck Priou
P304
P356
10.1016/S1470-2045(12)70560-0
P577
2013-01-08T00:00:00Z